Back to Journals » OncoTargets and Therapy » Volume 12

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment

Authors Cao Q, Liu Z, Huang Y, Qi C, Yin X

Received 26 October 2018

Accepted for publication 3 January 2019

Published 7 February 2019 Volume 2019:12 Pages 1071—1074


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Dr XuYu Yang

Qi Cao,1 Zhiguang Liu,1 Yanhua Huang,1 Chuang Qi,2 Xiaowei Yin1

1Department of Respiratory and Critical Care Medicine, Changzhou Second Affiliated People’s Hospital of Nanjing Medical University, Changzhou 213003, China; 2Medical Department, 3D Medicines, Shanghai 201100, China

Abstract: The heterogeneity of ALK tyrosine-kinase inhibitor (TKI) responses poses a puzzling question to clinicians. Different variants of ALK rearrangements might be one of the mechanisms explaining this phenomenon. Therefore, identifying specific fusion forms is crucial to clinical practice. This case report assesses the clinical efficacy of an ALK-TKI in a new ALK-rearrangement variant. Next-generation sequencing was performed in tumor tissue of one lung adenocarcinoma patient, and one new fusion form of an ALK rearrangement (NCOA1–ALK) was identified. This patient had progression-free survival >18 months with crizotinib treatment. Our findings provide valuable information about responses to crizotinib in patients with this form of ALK rearrangement and better understanding of ALK-TKI applications.

Keywords: NCOA1–ALK, lung adenocarcinoma, crizotinib

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]